A D S Diagnostic Share Price

India's economic growth to exceed 6.5% in FY26, says Moody's Ratings

Delhivery, Tata: Trading strategies in stocks that hit 52-week lows

Gensol Engineering shares plunge 50% in 12 days; rating downgrades weigh

Global funds' asset under custody see second-worst plunge amid market rout

Zydus Lifesciences to buy 86% stake in Amplitude Surgical for $280 million

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09 2015 we regret to inform you that the Company came to know about the sad demise of Mr. Ravi Kohli (DIN: 01012554) Independent Director of the Company. Mr. Ravi Kohli unexpected demise will be an irreparable loss to the Company and all the directors and employees of the Company convey deep sympathy sorrow and condolences to his family.

Dear Sir<BR> <BR> Please find herewith a copy of the approved unaudited financial result of the company and limited review report issued by M/s. V.N. Purohit & Co Chartered Accountant and statutory auditors of the company for the quarter/half year ended 30th September 2022 approved in its meeting of the board of directors dated 14th November 2022.<BR> <BR> The meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 14:35 p.m<BR>

Dear SirPlease find herewith a copy of the approved unaudited financial result of the company and limited review report issued by M/s. V.N. Purohit & Co Chartered Accountant and statutory auditors of the company for the quarter/half year ended 30th September 2022 approved in its meeting of the board of directors dated 14th November 2022.

ADS DIAGNOSTIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve In Pursuant to regulation 29(1)(a) of SEBI (Listing obligation and Disclosure Requirements)Regulation 2015 this is to inform you that the Meeting of Board of Directors of Company will beheld on Monday 14 November 2022 through Zoom application to consider and approve theFollowing.1. Unaudited Financial Results for quarter/ half year ended 30 September 2022.2. To consider any other business with the permission of the chair.

<table border=1><tr bgcolor=#d6d6d6><th class=TTRow_left> No.of Investor complaints pending at the beginning of the quarter </th><th class=TTRow> No.of Investor complaints received during the quarter</th><th class=TTRow> No.of Investor complaints disposed of during the quarter </th><th class=TTRow> No.of Investor complaints unresolved at the end of the quarter </th></tr><tr><td class=TTRow>0</td><td class=TTRow>1</td><td class=TTRow>0</td><td class=TTRow>1</td></tr></table><table border=1><tr><td > <span style=font-weight:bold>Name of the Signatory </span> </td><td> :- </td><td>N L GAYARI</td></tr><tr><td ><span style=font-weight:bold>Designation </span></td><td> :- </td><td>Company Secretary and Compliance Officer</td></tr></table>